

Supporting ED clinicians in buprenorphine prescribing

Supporting first time buprenorphine prescribers

Jeanmarie Perrone, MD,
Professor of Emergency Medicine
Director, Center for Addiction
Medicine and Policy
University of Pennsylvania
@JMPerroneMD

- I have received research funding from NIDA, CDC and SAMHSA
- I do not have any disclosures

Objectives

- Identify common barriers and pitfalls shared by potential buprenorphine prescribers
- Provide solutions and strategies to help guide buprenorphine administration and prescribing in clinicians with new DATA 2000 waivers




THE TREATMENT GAP


This E.R. Treats Opioid Addiction on Demand. That's Very Rare.


Some hospital emergency departments are giving people medicine for withdrawal, plugging a hole in a system that too often fails to provide immediate treatment.

Buprenorphine Implementation



Buprenorphine Rx Penn Medicine EDs






Overall, **89%** of eligible emergency physicians completed the X-waiver training during the 6-week incentive period.




Buprenorphine prescribing rates **increased to 15%** (from <1%) during the first 4 months of the program.

Prescription Rates by Month



After the incentive, buprenorphine prescribing per OUD encounter increased from **0.5% to 16%**.



Patient

Readiness, but faith


Clinician

Time and
knowledge

Bridge

Peers, timing

Identification: **automation**



Emergency rooms open new paths for opioid overdose survivors

Kim Painter, USA TODAY Published



Social

ED treatment: social norming

KATHLEEN LEE

Great job! Last week, you used your instincts and let recovery specialists know about a patient who needs support. That patient is still in contact and considering treatment options!



Biden administration will allow nearly all providers to prescribe buprenorphine

DATA 2000 WAIVER POLICY CHANGE

No training needed for < 30 patients

All About the X Waiver

What is an X Waiver?

An "X waiver" refers to the Drug Addiction Treatment Act (DATA 2000) "waiver" legislation that authorized the outpatient use of buprenorphine for the treatment of opioid use disorder.

What has changed? NEW Updated April 28, 2021

PennCAMP.org

**Now you are
waivered!!**

**Overcoming
barriers to
buprenorphine
prescribing....**

Patients frequently NOT in
withdrawal.

Patients decline due to “fear”
of PW due to fentanyl use.

Diversion? And patients
returning frequently

Buprenorphine Rx

	Nov. '17 – Nov. '18	Dec. '19 – Aug. '20
CRS consults	27	400
ED bupe admin	84	211
Bupe bridge scripts	12	209
Overdoses prevented	≈38	≈224


The NEW ENGLAND JOURNAL of MEDICINE

Interim Buprenorphine vs. Waiting List for Opioid Dependence

TO THE EDITOR: Opioid-use disorder has reached epidemic proportions, with high attendant costs in terms of increases in overdoses and infectious diseases and in economic costs.¹ Despite the demonstrated efficacy of maintaining abstinence by treating patients with opioid agonists, patients

can remain on clinic waiting lists for months, during which time they are at risk of premature death.² The use of interim treatment with buprenorphine without formal counseling while patients remain on waiting lists may mitigate this risk during delays in treatment.³


In a randomized pilot study (ClinicalTrials.gov number, NCT02360007), we evaluated the efficacy of an interim regimen of buprenorphine for reducing illicit opioid use among 50 persons on waiting lists for entry into treatment for opioid abuse. (The protocol is available with the full text of this letter at NEJM.org.) Participants had used opioids for a mean (\pm SE) of 7.2 ± 6.1 years, 78% had used intravenous opioids, and 30% had previously overdosed, with an average of 3.6 overdoses each. (Participant characteristics at baseline, including a history of drug use, are listed in the Supplementary Appendix, available at NEJM.org.) While remaining on the waiting list, 25 participants were randomly assigned to receive interim treatment with buprenorphine and 25




N ENGL J MED 375:25 NEJM.ORG DECEMBER 22, 2016

The New England Journal of Medicine

B Illicit-Opioid Use



C Intravenous Opioid Use








Universal Screening:












ED triage

Single Screen Question (SSQ)*:

*“In the past month
did you use a painkiller, heroin or fentanyl?”*



← → MedView  Results Review  SnapShot  ED Visit Consult Charting Chart Review  Dispo  ACP PDMP Follow Up Notes Report

ED Visit ?

 Refresh  Doc to Doc  MPM AVS  Print AVS  Tx Team |  Quick Vitals  Validate Data by Device  Review Visit  Consult Update


Document Disposition Clinical Scores

BANNERS

Banners  

This patient is in opioid withdrawal (COWS > or = to 8) Consider use of Buprenorphine orderset for treatment of withdrawal, order a Center for Opioid Recovery and Engagement consult, and use the Discharge OUD Smartset.

MYNOTE

Chief Complaint 

Orders

Provider Notes

Critical Care Time

Allergies

Home Medications


History

Procedure Notes

Attestation

Sign out notes

FOCUS

ED Provider Notes 

WEBSITES

Other barriers:



PATIENT HAS NO PLACE TO
FOLLOW UP?



PATIENT HAS NO
INSURANCE?

Covid





(484) 278-1679

City-Wide Warm Line


Reducing the barriers to
accessing treatment for
substance use in Philadelphia

Call to speak with a
Substance Use
Navigator who can
help connect patients
to care



Objectives:

- 100% Virtual
- Tele-Bupe
- Low Barrier
- Insurance not necessary



(484)278-1679

9AM-9PM

POLICY

Biden administration will allow nearly all providers to prescribe buprenorphine

DATA 2000 WAIVER POLICY
CHANGE

No training needed for < 30 patients

Bup 101: *Buprenorphine* *Basics*



Treatment Education for **APPs,**
Attending Physicians & Residents


Jeanmarie Perrone, MD, FACMT

Professor of Emergency Medicine
Director, Division of Medical Toxicology
University of Pennsylvania
[@JMPerroneMD](#)

INDEPENDENCE BLUE CROSS
FOUNDATION

Independence 



The hero section features a background image of a city skyline with a white line graph overlaid. The text "Our Vision" is centered above the main headline. Below the headline are three buttons: "CLINICAL", "EDUCATION", and "RESEARCH".

Our Vision

To substantially mitigate harms from substance use regionally and nationally.

CLINICAL EDUCATION RESEARCH

All About the X Waiver

What is an X Waiver?

An "X waiver" refers to the Drug Addiction Treatment Act (DATA 2000) "waiver" legislation that authorized the outpatient use of buprenorphine for the treatment of opioid use disorder.

What has changed? NEW Updated April 28, 2021



 Bup101
**Bup 101:
Buprenorphine
Basics**

Jeanmarie Perrone, MD, FACMT
Professor of Emergency Medicine
Director, Center for Addiction Medicine and Policy
University of Pennsylvania
@JMPerroneMD

Center for Addiction
Medicine and Policy

Watch on  YouTube

Watch later Share

Questions?

Thank You

Barriers to Buprenorphine Rx

- “Not sure how” and “I don’t think I am allowed”
- “It’s just one addiction for another”
- “I don’t have my X waiver”
- “What about diversion?”
- “What about follow up?”